Noteworthy Rating Filing: Is Juno Therapeutics (NASDAQ:JUNO) Worth Your Time After Placed SunTrust’s Downgrade?

November 25, 2016 - By Darrin Black

Noteworthy Rating Filing:  Is Juno Therapeutics (NASDAQ:JUNO) Worth Your Time After Placed SunTrust's Downgrade?

Juno Therapeutics (NASDAQ:JUNO) Downgrade

In an analyst note released today, SunTrust decreased shares of Juno Therapeutics (NASDAQ:JUNO) to Hold rating from Buy rating. The firm currently has a $25.0 PT on the stock. SunTrust’s PT gives a potential upside of 10.82% from the stock’s last stock close price.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 108.78% above today’s ($22.56) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. On Wednesday, November 18 the stock rating was initiated by Goldman Sachs with “Neutral”. The rating was maintained by FBR Capital on Friday, July 8 with “Outperform”. JP Morgan downgraded Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, July 8. JP Morgan has “Neutral” rating and $39 price target. The rating was maintained by Maxim Group on Friday, August 5 with “Buy”. The firm has “Buy” rating by Suntrust Robinson given on Friday, January 29. On Thursday, June 2 the stock rating was initiated by Raymond James with “Outperform”. The stock has “Hold” rating given by Standpoint Research on Thursday, October 29. FBR Capital initiated the stock with “Outperform” rating in Tuesday, August 18 report. The rating was downgraded by FBR Capital on Wednesday, November 23 to “Mkt Perform”. The rating was maintained by Maxim Group with “Buy” on Wednesday, November 23.

The stock decreased 24.50% or $7.32 during the last trading session, hitting $22.56. About 331 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.

Guggenheim Ltd Co, a Illinois-based fund reported 115,404 shares. Grp Inc One Trading Limited Partnership accumulated 0.03% or 57,501 shares. Shell Asset Mngmt Comm last reported 0.01% of its portfolio in the stock. Verition Fund Management Ltd Com last reported 0.03% of its portfolio in the stock. First Washington accumulated 39,700 shares or 0.88% of the stock. Checchi Advisers Limited Liability Corporation, a California-based fund reported 162 shares. Schwab Charles Invest Inc has 0.01% invested in the company for 234,448 shares. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 134,849 shares in the company. Jefferies Group Inc Ltd Liability Company holds 91,856 shares or 0.02% of its portfolio. First Republic Investment Mngmt Inc owns 5,935 shares or 0% of their US portfolio. Da Davidson And holds 12,018 shares or 0.01% of its portfolio. Winslow Evans Crocker holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 500 shares. Citadel Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Evercore Wealth Management Limited Co accumulated 0.03% or 18,937 shares. Ubs Asset Americas Inc holds 0% or 35,464 shares in its portfolio.

Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $1.80 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” with publication date: November 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>